GNOM stock forecast, quote, news & analysis

The most notable companies in this group are Gilead Sciences (NASDAQ:GILD), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

The average market capitalization across the Global X Genomics & Biotechnology ETF ETF is 11.53B. The market cap for tickers in the group ranges from 62.21M to 119.93B. VRTX holds the highest valuation in this group at 119.93B. The lowest valued company is BLUE at 62.21M.

The average weekly price growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was -10%. For the same ETF, the average monthly price growth was -13%, and the average quarterly price growth was -11%. NTRA experienced the highest price growth at 9%, while PACB experienced the biggest fall at -31%.

The average weekly volume growth across all stocks in the Global X Genomics & Biotechnology ETF ETF was 36%. For the same stocks of the ETF, the average monthly volume growth was 142% and the average quarterly volume growth was 150%